60-day scrips can mean fewer trips to the pharmacist and lower costs. But only one in five eligible scripts are for a 60-day supply. Here’s what’s going wrong.
Articles on Pharmaceuticals
Displaying 41 - 60 of 262 articles
All this talk of a US-Australia trade war has left consumers wondering what this means for them. At least in the short term, it looks like good news.
The next round of tariffs will breach the free trade agreement with the US. These sectors are next in line for new tariffs.
If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost down from around $500 a month to $31.60.
Medications degrade over time, meaning they may not work as intended once they reach and pass their expiry date.
Although quitting antidepressants can cause withdrawal symptoms, they are generally less severe than those of heroin.
Long-anticipated changes to how Australians buy paracetamol are on their way in a bid to reduce harms. Here’s what’s changing.
Antimicrobial resistance is yet another catastrophic legacy of war, threatening human health and security for generations to come.
A new study found people with type 2 diabetes who used drugs like Ozempic had a reduced risk of 42 health conditions or issues, but a greater risk of 19 others.
From nausea and vomiting to brain swelling and erection problems. These are just some of the side effects of melanotan-II.
Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and effective drugs.
The daily tablet can help reduce pain and inflammation caused by the chronic and often debilitating condition.
Since the 1980s very few antibiotics have been approved. One of the reasons is that there is not enough investment in the sector.
Both Trump and Harris seek to lower drug costs for patients. What headway have they made on realizing this goal?
Harris and Trump have starkly contrasting records on health care. This analysis examines their differing approaches to Medicare, the ACA, drug pricing and other public health efforts.
We need to take stock of the promises and limitations of new “miracle” weight loss drugs such as Ozempic, Mounjaro and Wegovy.
Long-term use of proton pump inhibitor drugs have been linked to kidney problems and cancer.
The Associate Health Minister’s letter of expectations for Pharmac includes things that could fundamentally alter its core objective of getting the best health outcomes within its budget.
When we mapped where Indigenous Australians are using a program to access free or discounted medicines, we found huge variation around the country. Here’s why that’s a problem.
The future of the blockbuster drugs could hinge on a trial in Pennsylvania.
Top contributors
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Director and Taylor Family Chair, Centre for the Business & Economics of Health, The University of Queensland
-
Lecturer Pharmacy Practice, University of Sydney
-
Conjoint Clinical Associate Professor, Deakin University School of Medicine and Specialist Pain Medicine Physician, Deakin University
-
Pharmacist and PhD Candidate, University of Sydney
-
Professor of Bioethics, Macquarie University
-
Assistant Professor of Resource Economics, UMass Amherst
-
Professor of Trade Law and Taxation, Queensland University of Technology
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
PhD Candidate, Swinburne University of Technology
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Senior Lecturer, Pharmacy, Aston University
-
Professor of Economics, Loughborough University